=>
Uploading C:\Program Files\Stnexp\Queries\11517010-updated.str





chain nodes :
19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 20 21 22 23 24 25
chain bonds :
11-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 9-12 10-11 10-15 12-13
13-14 14-15 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
5-7 6-11 7-8 8-9 10-11 11-19 19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-12 10-15 12-13 13-14 14-15 20-21 20-25
21-22 22-23 23-24 24-25
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom
25:Atom

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\11517010-not.str





```
chain nodes :
19
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  20  21  22  23  24  25
chain bonds :
11-19  19-20
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-11  7-8  8-9  9-10  9-12  10-11  10-15  12-13
13-14  14-15  20-21  20-25  21-22  22-23  23-24  24-25
exact/norm bonds :
5-7  6-11  7-8  8-9  10-11  11-19  19-20
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-12  10-15  12-13  13-14  14-15  20-21  20-25
21-22  22-23  23-24  24-25
isolated ring systems :
containing 1 : 20 :


G1:C,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  19:CLASS  20:Atom  21:Atom  22:Atom
23:Atom  24:Atom
25:Atom



L4      STRUCTURE UPLOADED

     FILE 'REGISTRY' ENTERED AT 12:16:43 ON 19 MAR 2008
L1              STRUCTURE UPLOADED
```

```
L2          889 S L1 SSS FULL

L4              STRUCTURE UPLOADED
L5          714 S L4 SSS FULL SUB=L2
L6          175 S L2 NOT L5

     FILE 'CAPLUS' ENTERED AT 12:18:30 ON 19 MAR 2008
L7            8 S L6
L8            1 S US200!-517010/APPS
L9            1 S L7 AND L8
L10           7 S L7 NOT L8

     FILE 'REGISTRY' ENTERED AT 12:19:09 ON 19 MAR 2008

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,N


Structure attributes must be viewed using STN Express query preparation.


=> d l4
L4 HAS NO ANSWERS
L4                STR
```



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:515475 CAPLUS <<LOGINID::20080319>>
DN 141:71360
TI Preparation of derivatives of and analogs of dibenzosuberone for use in pharmaceutical compositions as steroid hormone nuclear receptor modulators
IN Coghlan, Michael Joseph; Green, Jonathan Edward; Grese, Timothy Alan; Jadhav, Prabhakar Kondaji; Matthews, Donald Paul; Steinberg, Mitchell Irvin; Fales, Kevin Robert; Bell, Michael Gregory
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 457 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052847	A2	20040624	WO 2003-US16213	20030613
	WO 2004052847	A3	20040910		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489276	A1	20040624	CA 2003-2489276	20030613
	AU 2003302220	A1	20040630	AU 2003-302220	20030613
	BR 2003012095	A	20050329	BR 2003-12095	20030613
	EP 1519915	A2	20050406	EP 2003-810038	20030613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1665780	A	20050907	CN 2003-815098	20030613
	JP 2005539088	T	20051222	JP 2004-559025	20030613
	US 2006063759	A1	20060323	US 2004-517010	20041203 <--

	IN 2004KN01910	A	20070126	IN 2004-KN1910	20041213
	MX 2004PA12998	A	20050516	MX 2004-PA12998	20041217
	ZA 2004010293	A	20060222	ZA 2004-10293	20041221
	NO 2005000397	A	20050304	NO 2005-397	20050125
PRAI	US 2002-391992P	P	20020626		
	WO 2003-US16213	W	20030613		

OS MARPAT 141:71360

GI



I



II

AB Dibenzosuberone derivs., such as I [X = CH2; R, R1 = H, OH, CN, halogen, alkoxy, sulfonylamino, amino, etc.; R2 = aryl, heteroaryl; R3 = H, alkyl], and heterocyclic analogs thereof, such as I [X = O, S, NH, NMe, etc.], were prepared for therapeutic use in the treatment of pathol. disorders susceptible to steroid hormone nuclear receptor modulation. These compds. are claimed for use the treatment of disorders, such as Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic. congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melan in pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, rheumatoid arthritis, asthma, or chronic obstructive pulmonary disease,. Diastolic or systolic congestive heart failure, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic

dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis,. Bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus,, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multipie sclerosis. Thus, dibenzosuberone derivative II (R = NHMe) was prepared with 48%
yield via reaction of the corresponding sulfonyl chloride II (R = Cl) with MeNH2 in THF. The prepared dibenzosuberone derivs. and analogs were assayed for mineralocorticoid and glucocorticoid receptor binding.

=> d l10 tot bib abs hitstr

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:120489 CAPLUS <<LOGINID::20080319>>
DN 144:184724
TI Compounds as modulators of steroid hormone nuclear receptors
IN Michellys, Pierre-Yves; Petrassi, H. Michael; Richmond, Wendy; Pei, Wei
PA IRM LLC, Bermuda
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006015259	A2	20060209	WO 2005-US27086	20050728
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005267798	A1	20060209	AU 2005-267798	20050728
	CA 2574737	A1	20060209	CA 2005-2574737	20050728
	EP 1778242	A2	20070502	EP 2005-776623	20050728
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	BR 2005012674	A	20070925	BR 2005-12674	20050728
	IN 2007DN00633	A	20070803	IN 2007-DN633	20070123
	MX 200701129	A	20070419	MX 2007-1129	20070126
	KR 2007046150	A	20070502	KR 2007-704633	20070227
PRAI	US 2004-592076P	P	20040728		
	WO 2005-US27086	W	20050728		

OS MARPAT 144:184724
AB The invention provides compds., pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with the activation of steroid hormone nuclear

receptors.

IT 875437-10-8P 875437-11-9P 875437-12-0P
875437-13-1P 875437-14-2P 875437-15-3P
875437-16-4P 875437-17-5P 875437-18-6P
875437-19-7P 875437-20-0P 875437-22-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(steroid hormone nuclear receptors modulators for disease therapy)

RN 875437-10-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



RN 875437-11-9 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-fluoro- (CA INDEX NAME)



RN 875437-12-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (CA INDEX NAME)



RN 875437-13-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(Z)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cycloheptен-5-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-14-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cycloheptен-5-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-15-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(Z)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cycloheptен-5-ylidene]methyl]-8-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-16-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-8-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-17-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-8-methyl- (CA INDEX NAME)



RN 875437-18-6 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-(10,11-dihydro-2-hydroxy-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-19-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



RN 875437-20-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-2,2-dimethyl- (CA INDEX NAME)



RN 875437-22-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(2-fluoro-8-methoxydibenz[b,e]oxepin-

11(6H)-ylidene)methyl]-2,2,8-trimethyl- (CA INDEX NAME)



IT 875437-10-8D, hydrates, solvates and isomers 875437-11-9D
, hydrates, solvates and isomers 875437-12-0D, hydrates,
solvates and isomers 875437-13-1D, hydrates, solvates and
isomers 875437-14-2D, hydrates, solvates and isomers
875437-15-3D, hydrates, solvates and isomers 875437-16-4D
, hydrates, solvates and isomers 875437-17-5D, hydrates,
solvates and isomers 875437-18-6D, hydrates, solvates and
isomers 875437-19-7D, hydrates, solvates and isomers
875437-20-0D, hydrates, solvates and isomers 875437-22-2D
, hydrates, solvates and isomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(steroid hormone nuclear receptors modulators for disease therapy)
RN 875437-10-8 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-
5-ylidene)methyl]- (CA INDEX NAME)



RN 875437-11-9 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-
5-ylidene)methyl]-8-fluoro- (CA INDEX NAME)



RN 875437-12-0 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (CA INDEX NAME)



RN 875437-13-1 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(Z)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-14-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-15-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(Z)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-8-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-16-4 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-[10,11-dihydro-2-(phenylmethoxy)-5H-dibenzo[a,d]cyclohepten-5-ylidene]methyl]-8-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-17-5 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-8-methyl- (CA INDEX NAME)



RN 875437-18-6 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(E)-(10,11-dihydro-2-hydroxy-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-8-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 875437-19-7 CAPLUS
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



RN 875437-20-0 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-2,2-dimethyl- (CA INDEX NAME)



RN 875437-22-2 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[(2-fluoro-8-methoxydibenz[b,e]oxepin-11(6H)-ylidene)methyl]-2,2,8-trimethyl- (CA INDEX NAME)



L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:638871 CAPLUS <<LOGINID::20080319>>
DN 143:153374
TI Preparation of tricyclic steroid hormone nuclear receptor modulators
IN Gavardinas, Konstantinos; Green, Jonathan Edward; Jadhav, Prabhakar Kondaji; Matthews, Donald P.
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005066161	A1	20050721	WO 2004-US38233	20041208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004312293	A1	20050721	AU 2004-312293	20041208
CA	2549053	A1	20050721	CA 2004-2549053	20041208
EP	1697350	A1	20060906	EP 2004-811084	20041208

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN	1918151	A	20070221	CN 2004-80041853	20041208
BR	2004016882	A	20070227	BR 2004-16882	20041208
JP	2007515431	T	20070614	JP 2006-545655	20041208
US	20070037788	A1	20070215	US 2006-576761	20060421
MX	2006PA07055	A	20070130	MX 2006-PA7055	20060619
IN	2006DN03757	A	20070622	IN 2006-DN3757	20060629
NO	2006003329	A	20060914	NO 2006-3329	20060718
PRAI US	2003-531283P	P	20031219		
	WO 2004-US38233	W	20041208		

OS CASREACT 143:153374; MARPAT 143:153374

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = CH2, O; R1-2 = H, F; R3 = Z-amino, Z-heterocyclyl; Z = divalent alkyl; with some specific exceptions] are prepared For instance, II is prepared from (E)-11-bromomethylene-3-fluoro-6,11-dihydrodibenzo[b,e]oxepine (preparation given) and 1-(1,1-dimethyl-2-(morpholin-4-yl)ethyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-dihydrobenzimidazol-2-one (preparation given) (dioxane, Na2CO3, [Ph3P]4Pd, 90-100°, 5 days). II has Ki ≤ 500 nM for the mineralocorticoid receptor and Ki ≤ 1,000 nM for the glucocorticoid receptor. I are useful for the treatment of congestive heart disease, hypertension, rheumatoid arthritis or inflammation.

IT 710344-06-2P 860009-94-5P 860009-95-6P
860009-96-7P 860009-97-8P 860009-98-9P
860009-99-0P 860010-00-0P 860010-01-1P
860010-02-2P 860010-03-3P 860010-04-4P
860010-05-5P 860010-06-6P 860010-07-7P
860010-08-8P 860010-09-9P 860010-10-2P
860010-11-3P 860010-12-4P 860010-13-5P
860010-14-6P 860010-15-7P 860010-16-8P
860010-17-9P 860010-19-1P 860010-21-5P
860010-23-7P 860010-25-9P 860010-26-0P
860010-27-1P 860010-28-2P 860010-29-3P
860010-30-6P 860010-32-8P 860010-34-0P
860010-36-2P 860010-38-4P 860010-40-8P
860010-42-0P 860010-44-2P 860010-45-3P
860010-46-4P 860010-48-6P 860010-50-0P
860010-52-2P 860010-53-3P 860010-54-4P
860010-55-5P 860010-56-6P 860010-57-7P
860010-58-8P 860010-59-9P 860010-60-2P
860010-61-3P 860010-62-4P 860010-63-5P
860010-64-6P 860010-65-7P 860010-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolone-substituted tricyclic steroid hormone

nuclear receptor modulators)

RN 710344-06-2 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 860009-94-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-95-6 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-96-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-97-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(1-methyl-4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860009-98-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860009-99-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-00-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-01-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-02-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-03-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-04-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-05-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-06-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-07-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-08-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-09-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-10-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2S)-2-pyrrolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-11-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(2R)-2-pyrrolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-12-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-13-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-14-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-15-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-16-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-17-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-1,1-dimethylethyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-19-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-21-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-23-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-25-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-26-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(3-azetidinyl)-5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-27-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3R)-3-pyrrolidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 860010-28-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-29-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-30-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-32-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-34-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-36-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-38-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1R)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-40-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(1S)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-42-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[1,1-dimethyl-2-(4-morpholinyl)ethyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-44-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]ethyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-45-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-46-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[3-(1-piperazinyl)propyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-48-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 860010-47-5
CMF C28 H25 F2 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 860010-50-0 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 860010-49-7
CMF C27 H23 F2 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 860010-52-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-[(3R)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 860010-51-1
CMF C28 H25 F2 N3 O2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 860010-53-3 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 860010-54-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[3-(1-piperazinyl)propyl]- (CA INDEX NAME)



RN 860010-55-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 860010-56-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-[2-(dimethylamino)ethyl]-1,3-

dihydro- (CA INDEX NAME)



RN 860010-57-7 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 860010-58-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1,3-dihydro-1-[(3S)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 860010-59-9 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-

dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-[(3S)-1-ethyl-3-pyrrolidinyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 860010-60-2 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,8-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-61-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(1-ethyl-4-piperidinyl)-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-62-4 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 860010-63-5 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(2,8-difluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-1-(1-ethyl-4-piperidinyl)-1,3-dihydro- (CA INDEX NAME)



RN 860010-64-6 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3,7-difluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 860010-65-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[(3R)-1-ethyl-3-pyrrolidinyl]-5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860010-66-8 CAPLUS
CN 2H-Benzimidazol-2-one, 5-[(E)-(3-fluorodibenz[b,e]oxepin-11(6H)-ylidene)methyl]-1,3-dihydro-1-[(3R)-1-methyl-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:715726 CAPLUS <<LOGINID::20080319>>
DN 128:55376
TI Electrophotographic photoreceptor with improved charging stability and process cartridge and electrophotographic apparatus containing it
IN Kikuchi, Norihiro; Maruyama, Akio
PA Canon K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09281729	A	19971031	JP 1996-114403	19960412
JP 3273543	B2	20020408		
PRAI JP 1996-114403		19960412		

GI



AB The photoreceptor has a photosensitive layer containing a charge-generating agent, an arylamine I hole-transporting agent [Ar1-Ar3 = (substituted) aromatic ring, (substituted) heterocycle; R1-R2 = H, (substituted) alkyl, (substituted) alkoxy, halo; X = O, S, CH2CH2, CH:CH, :CR3R4; R3-R4 = H, (substituted) alkyl], a stilbenequinone II electron-transporting agent [R5-12 = (substituted) alkyl, (substituted) aralkyl, (substituted) aryl, (substituted) alkoxy, NO2, cyano, halo], and a binder resin. The process cartridge and the electrophotog. apparatus contain the photoreceptor. The photoreceptor showed improved charging stability and high sensitivity.

IT 120259-83-8
RL: DEV (Device component use); USES (Uses)
(hole-transporting agent; electrophotog. photoreceptor containing arylamine derivative and stilbenequinone derivative with improved charging stability)

RN 120259-83-8 CAPLUS

CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-bis(4-methylphenyl)- (CA INDEX NAME)



L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:609662 CAPLUS <<LOGINID::20080319>>

DN 125:261165

TI Electrophotographic photoreceptor

IN Hashimoto, Mitsuru

PA Matsushita Electric Ind Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 74 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08179527	A	19960712	JP 1994-322853	19941226
PRAI	JP 1994-322853		19941226		

GI



I

AB The electrophotog. photoreceptor comprises on its elec. conductive substrate a photosensitive layer containing I (R1 = amino, alkyl, cycloalkyl, hydroxy, acyl, carboxyl and its ester, aromatic hydrocarbon group, halo, CN, NO2; R2 and R3 may be same or different; R4 = aromatic hydrocarbon group, aromatic heterocyclic group; R3 and R4 may form a ring; m = 0-7; n = 1, 2). This photoreceptor shows good durability and high sensitivity.

IT 181930-69-8
RL: DEV (Device component use); USES (Uses)
(electrophotog. photoreceptor from)

RN 181930-69-8 CAPLUS

CN 9,10-Anthracenedione, 2-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]- (CA INDEX NAME)



L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:113269 CAPLUS <<LOGINID::20080319>>

DN 124:160306

TI Electrophotographic photoreceptor and apparatus using the same

IN Kanamaru, Tetsuo; Nakada, Koichi; Kikuchi, Norihiro

PA Canon Kk, Japan

SO Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07281462	A	19951027	JP 1994-93884	19940408
PRAI	JP 1994-93884		19940408		

GI



I

AB In the electrophotog. photoreceptor having a photosensitive layer on a conductive support, the photosensitive layer contains a styryl compound I (X = CH2CH2, HC:CH; R1,2 = alkyl, aralkyl, aromatic, heterocyclyl; R3,4 = H, halo, alkyl, alkoxy; Ar1 = aromatic, heterocyclyl) and a triaryl compound Ar2Ar3NAr4 (Ar2,3,4 = Ph, in which ≥2 of Ph contains C2-4 alkyl) as a charge-transporting substance. The electrophotog. photoreceptor provided a charge-transporting layer free of crack and crack formation.

IT 120259-83-8
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(charge-transporting substance in electrophotog. photoreceptor)

RN 120259-83-8 CAPLUS

CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-bis(4-methylphenyl)- (CA INDEX NAME)



L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1992:184238 CAPLUS <<LOGINID::20080319>>

DN 116:184238

TI Organic electroluminescent device

IN Ota, Masabumi; Onuma, Teruyuki; Kawamura, Fumio; Sakon, Hirota; Takahashi, Toshihiko

PA Ricoh Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03200889	A	19910902	JP 1990-49796	19900228
	JP 2897138	B2	19990531		
	US 5093210	A	19920303	US 1990-544905	19900628
PRAI	JP 1989-168826	A1	19890630		
	JP 1989-168827	A1	19890630		
	JP 1990-49796	A	19900228		

OS MARPAT 116:184238
GI



I

AB The device, suited for use in large-area displays, comprises ≥1 organic compound layer sandwiched between a pair of electrodes, wherein ≥1 layer consists of R1R2NAr1(CH:CH)nAr2 or I [R1-5 = (un)substituted alkyl, carbocyclic aromatic ring, heterocyclic aromatic ring; R1, R2 may form a ring; Ar1-2 = (un)substituted carbocyclic aromatic ring, heterocyclic aromatic ring; n = 1-3; X = C2H4,CH:CH,O,S,NR5].
IT 140188-77-8
RL: PRP (Properties)
(hole-transporting layer from, for organic electroluminescent device)
RN 140188-77-8 CAPLUS
CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-diphenyl- (CA INDEX NAME)



AN 1989:202799 CAPLUS <<LOGINID::20080319>>
DN 110:202799
TI Organic electrophotographic photoreceptor containing charge-transporting triarylamine
IN Goto, Satoshi; Sasaki, Osamu; Suzuki, Shinichi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63235945	A	19880930	JP 1987-70569	19870324
PRAI JP 1987-70569		19870324		

GI



I

AB The title photoreceptor has a photosensitive layer containing a compound of the formula I (R1 = H, halo, alkyl, alkoxy; R2 = H, alkyl, aryl; R3, R4 = aryl; Z = phenylene, naphthylene; n = 0, 1, 2).
IT 120259-83-8
RL: USES (Uses)
(electrophotog. charge-transporting substance)
RN 120259-83-8 CAPLUS
CN 1-Naphthalenamine, 4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methyl]-N,N-bis(4-methylphenyl)- (CA INDEX NAME)


CH
N
Me
Me